Original research
Dermatology
Original research relevant to this speciality, newest first.
- Chronic immune-related toxicity affects nearly half of patients receiving adjuvant anti–PD-1 for melanoma
JAMA Network Open
Multicentre cohort, 303 patients. Chronic adverse events occurred in 48%, supporting continued monitoring after treatment ends. - Major pathological response after neoadjuvant melanoma immunotherapy predicts excellent five-year survival
Nature Medicine
Pooled analysis, 1,038 patients. Five-year survival approached 98–99% among major responders to checkpoint inhibitors. Comparisons between treatment regimens were not randomized.